新型药物时代弥漫性大B细胞淋巴瘤的治疗排序
本文综述了弥漫性大B细胞淋巴瘤(DLBCL)的新型药物,包括单克隆抗体、抗体偶联药物(ADC)、双特异性T细胞衔接器(BITEs)和靶向CD19的嵌合抗原受体(CAR)T细胞疗法,并概述了从一线到二线、三线及后线治疗的潜在排序。
要点
- DLBCL约占成人侵袭性淋巴瘤的40%,约三分之二患者可通过一线治疗治愈。
- 约三分之一患者为原发难治或初始缓解后复发(r/r DLBCL)。
- 新型药物增多显著改善了患者结局,但治疗算法日益复杂。
核心结论
- 本文提供了DLBCL新型疗法的概述及从一线到二线、三线及后线治疗的潜在排序。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- DLBCL是最常见的侵袭性淋巴瘤,约占成人所有病例的40%。
- 约三分之二DLBCL患者可通过一线治疗治愈,三分之一为原发难治或初始缓解后复发。
- 新型药物包括单克隆抗体、抗体偶联药物(ADC)、双特异性T细胞衔接器(BITEs)和靶向CD19的CAR-T细胞疗法。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma, accounting for ~40% of all cases in adults. Whilst approximately two-thirds of DLBCL patients can be cured by first-line therapy, one-third of patients are primary refractory or relapse after an initial response (r/r DLBCL). Recent advances in the treatment of DLBCL have been achieved by a plethora of novel drugs, such as monoclonal antibodies, antibody-drug conjugates (ADC), bi-specific T-cell engagers (BITEs), and CD-19 directed chimeric antigen receptor (CAR)-T-cell therapies. The increasing number of therapeutic options significantly improved the outcome of patients; however, the therapeutic algorithm has become increasingly complex. In this review, we provide an overview of novel therapies for DLBCL patients and potential treatment sequencing from first to second, third, and later lines.
引用
- Karsten IE, Shumilov E, Schmitz N, et al. Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs. Br J Haematol. 2024. PMID: 39466716. doi:10.1111/bjh.19860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。